Evaluating the performance of the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA les (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with Non-ST-Segment elevation acute myocardial infarction

Circulation

Volumn 121, Issue 22, 2010, Pages 2419-2426

  Abu Assi, Emad ^a   Gracía Acuña, José María ^a   Ferreira González, Ignacio ^d   Peña Gil, Carlos ^a   Gayoso Diz, Pilar ^b,c   González Juanatey, José Ramón ^a  

^a Cardiology Department   (Australia)

^b Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

CRUSADE risk score; Major bleeding; Myocardial infarction

Indexed keywords

ANTICOAGULANT AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CALIBRATION; CARDIOVASCULAR RISK; FEMALE; HEART CATHETERIZATION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVASCULARIZATION; SCORING SYSTEM; SPAIN; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HEALTH PLANNING GUIDELINES; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953356844     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.925594     Document Type: Article

References (30)

1. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV Jr., Peterson ED, Alexander K. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) bleeding score. Circulation. 2009;119:1873-1882.
2. Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28: 1193-1204.
3. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782.
4. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Mon-talescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815-1823.
5. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200-1206. (Pubitemid 41505393)
6. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes: variations in practice and outcome: findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23:1177-1189. (Pubitemid 35215244)
7. Fox KA, Goodman SG, Anderson FA Jr, Granger CB, Moscucci M, Flather MD, Spencer F, Budaj A, Dabbous OH, Gore JM, for the GRACE Investigators. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1414-1424.
8. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol. 2009;54:1209-1227.
9. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92:1752-1759.
10. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W, for the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809-1840.
11. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F. Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007;28:1598-1660.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
13. Lemeshow S, Hosmer D. A review of goodness of fit statistic for use in the development of logistic regression models. Am J Epidemiol. 1982; 115:92-106.
14. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
15. R Development Core Team (2009). R: A Language and Environment for Stadistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: http//www.R-project.org. Accessed November 1, 2009.
16. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, Lincoff AM, Stone GW. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28:1936-1945.
17. Ferreira-González I, Permanyer-Miralda G, Marrugat J, Heras M, Cuñat J, Civeira E, Arós F, Rodŕ?guez JJ, Sánchez PL, Bueno H, for the MASCARA study research team. MASCARA (Manejo del Síndrome Coronario Agudo, Registro Actualizado) study: general findings. Rev Esp Cardiol. 2008;61:803-816.
18. Goldberg RJ, Currie K, White K, Brieger D, Steg PG, Goodman SG, Dabbous O, Fox KA, Gore JM. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2004;93:288-293.
19. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Circulation. 2007;116:e148-e304.
20. Rao RV. Strategies to reduce bleeding among patients with ischemic heart disease treated with antiplatelet therapies. Am J Cardiol. 2009;104: 60C-63C.
21. White HD. Strategies to minimize bleeding complications of percutaneous coronary intervention. Curr Opin Cardiol. 2009;24:273-278.
22. Rao SV, Ou FS, Wang TY, Roe MT, Brindis R, Rumsfeld JS, Peterson ED. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. J Am Coll Cardiol Cardiovasc Interv. 2008;1:379-386.
23. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355: 2203-2216.
24. Stone GW, Witzenbichler B, Guiagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.
25. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-1476.
26. Maxwell CB, Holdford DA, Crouch MA, Patel DA. Cost-effectiveness analysis of anticoagulant strategies in non-ST-elevation acute coronary syndromes. Ann Pharmacother. 2009;43:586-595.
27. Huston SA, Hawkins D. Pharmacoeconomics of anticoagulant in acute coronary syndrome and percutaneous coronary intervention. Curr Pharmaceutical Design. 2008;14:1197-1204.
28. Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ, for the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators. Economic evaluation of biva-lirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008;52: 1758-1768.
29. Sculpher MJ, Lozano-Ortega G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, Flather M, Steg PG, Mehta SR, Weintraub W. Fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J. 2009;157:845-852.
30. Schuster DP. Predicting outcome after ICU admission: the art and science of assessing risk. Chest. 1992;102:1861-1870.